I know Baillieu updated their clients with a small synopsis on...

I know Baillieu updated their clients with a small synopsis on the day on the Ann. They have been on this for a long time. Still mainting a spec risk profile until they have a better understanding of sales structure.

Rating: BUY Price Target: $0.50 Risk: Speculative Share Price: $0.29

A snippet;
"Whilst not quite what we expected, the rationale appears sound. We understand that the direct sales force will be in place and ready to sell BTM within a few weeks with a strong emphasis to commission. Apart from taking the time to decide on direct distribution we understand the delay between FDA approval and commercial sales has been driven by the need to establish a US operating entity. We continue to view the product as unique with global appeal and multiple potential applications other than burn treatment. Our speculative rating will be retained until we can evaluate the early phases of commercialisation. "

The market has since digested and warmed up to the news after the initial unexpected descision.
Would be great to know if other brokers were also looking into the company.